Analyzing Jushi (JUSHF) & Its Competitors

Jushi (OTCMKTS:JUSHFGet Free Report) is one of 55 public companies in the “Medicinals & botanicals” industry, but how does it weigh in compared to its rivals? We will compare Jushi to similar businesses based on the strength of its analyst recommendations, dividends, risk, earnings, profitability, institutional ownership and valuation.

Risk & Volatility

Jushi has a beta of -0.16, suggesting that its share price is 116% less volatile than the S&P 500. Comparatively, Jushi’s rivals have a beta of 1.36, suggesting that their average share price is 36% more volatile than the S&P 500.

Institutional and Insider Ownership

21.7% of Jushi shares are held by institutional investors. Comparatively, 16.1% of shares of all “Medicinals & botanicals” companies are held by institutional investors. 21.0% of Jushi shares are held by insiders. Comparatively, 22.4% of shares of all “Medicinals & botanicals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Jushi and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Jushi -24.16% -320.66% -10.31%
Jushi Competitors -45.53% -60.43% -9.08%

Earnings and Valuation

This table compares Jushi and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Jushi $269.45 million -$65.10 million -2.03
Jushi Competitors $309.02 million -$154.30 million -10.35

Jushi’s rivals have higher revenue, but lower earnings than Jushi. Jushi is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Jushi and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jushi 0 2 0 0 2.00
Jushi Competitors 246 546 920 66 2.45

As a group, “Medicinals & botanicals” companies have a potential upside of 74.79%. Given Jushi’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Jushi has less favorable growth aspects than its rivals.

Summary

Jushi rivals beat Jushi on 9 of the 13 factors compared.

About Jushi

(Get Free Report)

Jushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of medical and adult-use products. It focuses on building a portfolio of cannabis assets in various jurisdictions in Pennsylvania, Virginia, Ohio, Illinois, California, Nevada, and Massachusetts. The company also offers hemp-based CBD products, including cannabis dry flower, vaporizer forms of cannabis, edibles, cannabis oil in capsules, tinctures, cannabis in topical products, and other cannabis products, as well as vape cartridges, disposables, and concentrates under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. In addition, it operates medical cannabis dispensaries under the BEYOND/HELLO, Nature's Remedy, and NuLeaf brands. The company is headquartered in Boca Raton, Florida.

Receive News & Ratings for Jushi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jushi and related companies with MarketBeat.com's FREE daily email newsletter.